2022 annual financial data
BioMarin Pharmaceutical 2022 Operating cash flow margin
Direct answer
Operating cash flow margin was 8.39%.
Operating income was 160,974,000 USD and net income was 141,561,000 USD.
Operating cash flow was 175,902,000 USD.
Get free BioMarin Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,096,039,000 USD
- Operating income
- 160,974,000 USD
- Net income
- 141,561,000 USD
- Operating cash flow
- 175,902,000 USD